Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) EVP Rong Zhou sold 2,173 shares of the stock in a transaction on Friday, November 9th. The stock was sold at an average price of $20.50, for a total transaction of $44,546.50. Following the sale, the executive vice president now directly owns 54,392 shares of the company’s stock, valued at approximately $1,115,036. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Amphastar Pharmaceuticals stock opened at $21.21 on Wednesday. The firm has a market capitalization of $971.39 million, a P/E ratio of 105.00, a price-to-earnings-growth ratio of 9.82 and a beta of 1.38. Amphastar Pharmaceuticals Inc has a 1-year low of $14.40 and a 1-year high of $21.65. The company has a quick ratio of 1.34, a current ratio of 2.02 and a debt-to-equity ratio of 0.10.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Thursday, November 8th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01. The business had revenue of $75.54 million during the quarter, compared to the consensus estimate of $76.84 million. Amphastar Pharmaceuticals had a negative net margin of 2.33% and a positive return on equity of 2.80%. The firm’s revenue for the quarter was up 30.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.07 earnings per share. On average, research analysts anticipate that Amphastar Pharmaceuticals Inc will post 0.1 earnings per share for the current year.

Several equities research analysts have recently issued reports on AMPH shares. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 10th. BidaskClub raised shares of Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 27th. Needham & Company LLC set a $25.00 price objective on shares of Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, November 9th. ValuEngine raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, August 17th. Finally, Wells Fargo & Co reissued a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Friday, November 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Amphastar Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $23.00.

A number of institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC grew its position in Amphastar Pharmaceuticals by 104.3% in the third quarter. Renaissance Technologies LLC now owns 186,100 shares of the company’s stock valued at $3,581,000 after purchasing an additional 95,000 shares in the last quarter. Allianz Asset Management GmbH grew its position in Amphastar Pharmaceuticals by 15.1% in the third quarter. Allianz Asset Management GmbH now owns 110,465 shares of the company’s stock valued at $2,125,000 after purchasing an additional 14,495 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Amphastar Pharmaceuticals by 7.9% in the third quarter. Dimensional Fund Advisors LP now owns 1,909,883 shares of the company’s stock valued at $36,746,000 after purchasing an additional 140,350 shares in the last quarter. BlackRock Inc. grew its position in Amphastar Pharmaceuticals by 4.7% in the third quarter. BlackRock Inc. now owns 5,987,805 shares of the company’s stock valued at $115,205,000 after purchasing an additional 267,622 shares in the last quarter. Finally, Martingale Asset Management L P bought a new position in Amphastar Pharmaceuticals in the third quarter valued at $2,033,000. 42.89% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2018/11/14/insider-selling-amphastar-pharmaceuticals-inc-amph-evp-sells-2173-shares-of-stock.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Recommended Story: How can investors find ex-dividend dates?

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.